LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
USA - NASDAQ:LGND - US53220K5048 - Common Stock
181.65 USD
+0.88 (+0.49%)
181.65 USD
0 (0%)
LGND gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While LGND has a great health rating, its profitability is only average at the moment. LGND is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
In the past year LGND had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
Each year in the past 5 years LGND had a positive operating cash flow.
1.2 Ratios
The Return On Assets of LGND (-8.00%) is better than 69.23% of its industry peers.
Looking at the Return On Equity, with a value of -9.16%, LGND is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGND's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 93.05%, LGND belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LGND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LGND has been increased compared to 1 year ago.
LGND has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 18.98 indicates that LGND is not in any danger for bankruptcy at the moment.
LGND has a Altman-Z score of 18.98. This is amongst the best in the industry. LGND outperforms 91.28% of its industry peers.
There is no outstanding debt for LGND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 18.98 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 5.45 indicates that LGND has no problem at all paying its short term obligations.
LGND's Current ratio of 5.45 is fine compared to the rest of the industry. LGND outperforms 71.79% of its industry peers.
LGND has a Quick Ratio of 5.21. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND has a better Quick ratio (5.21) than 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.80%, which is quite impressive.
The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 40.53%.
Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
3.2 Future
The Earnings Per Share is expected to grow by 14.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.16% on average over the next years. This is a very strong growth
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LGND is valuated quite expensively with a Price/Earnings ratio of 30.07.
LGND's Price/Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 80.00% of the companies in the same industry.
LGND's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.42.
A Price/Forward Earnings ratio of 23.41 indicates a rather expensive valuation of LGND.
Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 72.31% of the companies are valued more expensively.
LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.07 | ||
| Fwd PE | 23.41 |
4.2 Price Multiples
LGND's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LGND is cheaper than 76.41% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 77.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.02 | ||
| EV/EBITDA | 155.09 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 15.36% in the coming years.
PEG (NY)1.33
PEG (5Y)2.24
EPS Next 2Y16.57%
EPS Next 3Y15.36%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
181.65
+0.88 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.32%
Inst Owner Change-0.28%
Ins Owners1.69%
Ins Owner Change0.43%
Market Cap3.56B
Analysts84.62
Price Target186.79 (2.83%)
Short Float %5.86%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)0%
PT rev (3m)27.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.74%
EPS NY rev (1m)0.04%
EPS NY rev (3m)12.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.07 | ||
| Fwd PE | 23.41 | ||
| P/S | 18.98 | ||
| P/FCF | 70.02 | ||
| P/OCF | 67.71 | ||
| P/B | 4.3 | ||
| P/tB | 12.57 | ||
| EV/EBITDA | 155.09 |
EPS(TTM)6.04
EY3.33%
EPS(NY)7.76
Fwd EY4.27%
FCF(TTM)2.59
FCFY1.43%
OCF(TTM)2.68
OCFY1.48%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.33
PEG (5Y)2.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% | ||
| FCFM | 27.11% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.04% | ||
| Cap/Sales | 0.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 259.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 18.98 |
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year478.11%
EBIT Next 3Y137.22%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A